XtalPi and Lingxi Cloud Collaborate to Build a Novel Neurotherapeutic Drug Discovery Platform Targeting Challenging Neurological Disorders

Recently, XtalPi Holdings Limited ("XtalPi"), which drives innovative R&D through AI and robotics,”, Stock Abbreviation: XtalPi Holdings-P, XTALPI-P, 2228.HK) announced a research and development collaboration with BrainAI, an artificial intelligence company in the field of brain science. By integrating AI algorithms with EEG BioMarker recognition models, the two parties will jointly explore the construction of a neuro-drug screening platform based on cellular platforms and digital brain models. This platform can not only be applied in the early stage of drug development but also provide precise patient screening solutions for clinical trials, addressing challenges such as the high difficulty of neuro-related drug screening and low success rates in clinical trials, thereby accelerating breakthroughs in the treatment of neurological disorders.

Lingxi Cloud was founded in 2019 by renowned scientists Hong Bo, Lu Bai, and Zhang Hongjiang. It is an international leader in brain-computer interface big data and large-scale models. The company is committed to building a unified underlying operating system platform for brain-computer interfaces, focusing on the field of medical brain-computer big data. It is a leading provider of clinical EEG big data center solutions and a brain-computer precision drug research and development service enterprise in the industry. Centered around "neurological diseases + brain function big data + neurodynamic brain-computer large models," it analyzes complex brain function activities through EEG signals, overcoming the limitations of traditional medical diagnostic models based on manual annotations. Innovatively, it serves application scenarios such as depression, bipolar disorder, Alzheimer's disease, and pediatric genetic developmental brain disorders, where there are currently no effective objective diagnostic indicators.

XtalPi, as a pioneer in intelligence and automation in the life sciences field, has independently built an innovative R&D platform using cutting-edge technologies such as artificial intelligence, quantum physics, and robotic experiments. XtalPi's large-scale AI robotics laboratory continuously accumulates real-world data, constructing large models in vertical fields through larger-scale, higher-throughput, and higher-quality experimental data, and has accumulated rich experience in multiple areas of life science research. Currently, XtalPi has established long-term cooperative relationships with many of the world’s top pharmaceutical companies, including Pfizer, Eli Lilly, Johnson & Johnson, Merck, and Novartis.

XtalPi Innovation Center (XIC) has been committed to applying cutting-edge AI technologies to more challenging fields, with a particular focus on central nervous system (CNS)-related diseases as an important direction. CNS-related diseases are diverse and involve complex neural network mechanisms. Additionally, the lack of clinically relevant preclinical models significantly increases the risks in drug development. To address this, XtalPi Innovation Center actively explores the construction of in vitro models with better clinical relevance and has established the high-throughput AI cell platform MoXyte™: In terms of experimental technology, an advanced Cell Painting high-throughput screening platform has been built; in the algorithm domain, pre-trained models such as X-Profiler for cellular image phenotypes, SC-MAMBA for cellular omics data, and design algorithms targeting intrinsically disordered proteins (IDPs) have been developed. Through these advanced technologies and platforms, XtalPi has established extensive collaborations in key areas such as drug screening, target discovery, mechanism analysis, and safety evaluation, accumulating rich practical experience.

The powerful collaboration between XtalPi and Lingxun Cloud, focusing on drug development for neurological diseases, marks a significant step of innovative breakthrough in this field, with far-reaching strategic significance.。

In the field of medical research, drug development for neurological disorders has always been a challenging problem for scientists. Due to the wide variety of neurological disorders and their involvement in complex neural network mechanisms, traditional drug development methods often struggle to accurately simulate the disease process, making the transition from preclinical research to clinical application a bottleneck in the development process. Additionally, the lack of preclinical models that correlate with clinical efficacy significantly increases the risks associated with drug development.

To solve this problem, Lingxi Cloud and XtalPi have joined hands to fully leverage the complementary advantages of both parties in technology and resources, and jointly build a neuro-drug screening platform based on cell platforms and digital brain models. The platform will integrate EEG signals from clinical patients to construct in vitro models highly correlated with clinical outcomes, simulating the pathogenesis of neurological diseases with precision to assist pharmaceutical companies in patient selection, disease target identification, and drug choice. This collaboration will also conduct small-scale clinical studies on candidate diseases and drugs to precisely optimize clinical trial designs.

We believe that, with the strong collaboration and joint efforts of both parties, this platform will continue to innovate, drive technological breakthroughs, and advance research progress, bringing new opportunities and hope to the field of drug development for neurological disorders.